MIT Biotechnology Group

Cancer Nanomedicine Distinguished Seminar, May 21, 5 pm, 76-156

From Cancer Dependence to Cancer Therapeutics
Dr. William Sellers
https://www.broadinstitute.org/bios/william-sellers

76-156, Koch Institute auditorium, MIT
5-6 PM
Free food/dessert/beverages.

The Marble Center kicks off this year’s Distinguished Seminar Series with a lecture by Dr. William Sellers entitled “From Cancer Dependence to Cancer Therapeutics.” Dr. Sellers is a Core Institute Member at the Broad Institute and a Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School, where he runs a research group focused on translating genomic discoveries into new therapeutics. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for BioMedical Research overseeing scientists, clinicians and clinical staff on sites in Cambridge, East Hanover, Basel and Shanghai from 2005-2016. Since he joined Novartis in 2005, the oncology research group has brought more than 30 small molecule, biologic and cell-based cancer therapeutics into first-in-human trials, including therapeutics targeting the PI3K, CDK4, IDH, ABL, SMO, HER3, ALK, Wnt, PIM and Ras pathways among others. During his tenure, he conceptualized and directed the collaboration with the Broad Institute on the Cancer Cell Line Encyclopedia, the development of the Novartis Primary Derived Xenograft Encyclopedia, and large-scale efforts to functionally characterize the cancer genome. Along with Dr. Carl June, he co-chaired the CART collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval.

More info at: https://nanomedicine.mit.edu/events-announcements

Leave a Reply